Want to see OSG full AI Analyst Report?
Top Page
Octave Specialty Group
(NYSE:OSG)
Select Model
Select Model
Rating:58Neutral
Price Target:
$7.00
▲(77.66% Upside)
Action:Reiterated
Date:06/27/26
OSG’s score is most constrained by weak financial quality—deep losses and recently negative operating/free cash flow—despite strong revenue momentum and a de-risked consolidated balance sheet. Technicals are supportive with a bullish trend and positive MACD, but momentum is nearing overbought. The earnings call was a positive catalyst (sharp improvement in segment profitability and narrowed GAAP loss), while valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
Top-line Growth
Sustained revenue acceleration, driven by 42% organic Insurance Distribution growth and the ArmadaCare acquisition, improves scale and diversification. Durable top-line momentum supports underwriting leverage, funds platform investments and M&A, and underpins recovery of margins over a multi-quarter horizon.
Negative Factors
Negative Cash Generation
Sustained negative operating and free cash flow materially constrains internal funding for underwriting, MGA launches and integration. Continued cash burn will require external financing or equity, increasing dilution or leverage risk and limiting durable margin recovery if not reversed within upcoming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line Growth
Sustained revenue acceleration, driven by 42% organic Insurance Distribution growth and the ArmadaCare acquisition, improves scale and diversification. Durable top-line momentum supports underwriting leverage, funds platform investments and M&A, and underpins recovery of margins over a multi-quarter horizon.
Read all positive factors
Octave Specialty Group (OSG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$274.58M
Dividend YieldN/A
Average Volume (3M)600.26K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth-15.66%
EPS Growth-2451.62%
CountryUS
Employees483
SectorFinancial
Sector Strength70
IndustryInsurance - Specialty
Share Statistics
EPS (TTM)-4.85
Shares Outstanding45,013,590
10 Day Avg. Volume614,155
30 Day Avg. Volume600,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)1.46
P/FCF Ratio-7.02
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit1.20
Enterprise Value/Ebitda-9.55
Forecast
1Y Price Target
$13.50Price Target Upside242.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.28
Revenue Forecast (FY)$82.07M
Octave Specialty Group Business Overview & Revenue Model
Company Description
Octave Specialty Group, Inc. functions as a financial services holding company, organizing its operations into two distinct divisions. Its Specialty Property and Casualty Insurance segment delivers specialized program insurance, primarily focusing...
How the Company Makes Money
null...
Octave Specialty Group Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call presented a strong operational and financial improvement story: very large revenue and adjusted-EBITDA gains in the Insurance Distribution segment, narrower GAAP losses, premium growth and loss-ratio improvement at Everspan on a pro forma basis, cost reductions, expanded capacity, and continued strategic progress on platform and AI initiatives. The quarter did include notable one-off headwinds — primarily a litigation settlement and related legal costs that materially inflated reported loss ratios, early-stage losses from newly launched MGAs, and ongoing non-recurring charges — but management quantified these items and highlighted pro forma metrics showing more normalized performance. On balance, the positive operational momentum and material improvements in non‑GAAP profitability and margins significantly outweigh the quarter’s lowlights.Positive Updates
Insurance Distribution Revenue Surge
Total revenues for the Insurance Distribution segment grew 92% year-over-year to $78.5 million in Q1 2026, driven by organic growth of 42% and the October 2025 acquisition of ArmadaCare.
Negative Updates
Reported GAAP Headline Loss and Everspan Pre-Tax Loss
Company still reported a GAAP net loss to shareholders of $6.9 million in Q1 2026. Everspan produced a pre-tax loss of $8 million for the quarter, indicating continuing headwinds in that business.
Read all updates
Q1-2026 Updates
Positive
Negative
Insurance Distribution Revenue Surge
Total revenues for the Insurance Distribution segment grew 92% year-over-year to $78.5 million in Q1 2026, driven by organic growth of 42% and the October 2025 acquisition of ArmadaCare.
Read all positive updates
Company Guidance
Management said 2026 guidance remains essentially unchanged from the February outlook, though Q1 came in ahead of plan and they will consider adjusting guidance in coming quarters; Q1 strength was led by Insurance Distribution where revenue rose 92% to $78.5M (42% organic growth) helped by the ArmadaCare acquisition (ArmadaCare organic +10%), driving Insurance Distribution adjusted EBITDA to $25.3M (≈32% margin) and pre-tax margin to 16.3%. Consolidated results improved materially — net loss narrowed to $6.9M (‑$0.13/sh) versus a $16.1M loss a year ago, consolidated EBITDA was $3.6M and consolidated adjusted EBITDA $20.1M, with adjusted net income $16.6M or $0.37/sh. For the year they expect organic growth to be the primary driver, A&H to represent ~30% of production, target 1–2 de novo MGA launches in 2026 (de novo costs reduced EBITDA by ~$1.1M in Q1), and no further NCI buy‑ins planned after the ~$44M spent this quarter; Insurance Distribution pro forma net debt/EBITDA was ~3.2x, bank spreads are ~275bps over SOFR, total available capacity has expanded from $1.5B to over $2B, and seasonality remains (Q1 strongest, Q4 second). Finally, Everspan’s Q1 metrics (GWP $104M, NPW $32M, NPE $20M) and a pro forma combined ratio ≈95% (accident year loss ratio ~54%, active programs ~57%) underpin the view that repositioning is on track.Octave Specialty Group Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 292.63M | 251.22M | 235.81M | 124.73M | 53.61M | 247.00M |
| Gross Profit | 230.09M | 204.03M | 98.65M | 47.99M | 24.36M | 319.00M |
| EBITDA | -28.99M | -40.42M | -30.52M | -18.99M | -31.91M | 246.00M |
| Net Income | -199.33M | -240.92M | -556.45M | 3.63M | 521.25M | -17.00M |
Balance Sheet | ||||||
| Total Assets | 2.27B | 2.22B | 8.06B | 8.43B | 7.97B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 322.92M | 337.18M | 331.90M | 354.96M | 1.93B | 1.85B |
| Total Debt | 117.06M | 117.56M | 150.00M | 3.48B | 3.75B | 6.45B |
| Total Liabilities | 1.24B | 1.14B | 6.86B | 7.00B | 6.65B | 11.19B |
| Stockholders Equity | 712.62M | 715.79M | 856.91M | 1.36B | 1.25B | 1.04B |
Cash Flow | ||||||
| Free Cash Flow | -49.75M | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Operating Cash Flow | -49.75M | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Investing Cash Flow | 205.28M | 199.94M | -166.37M | 435.00M | -41.16M | 776.00M |
| Financing Cash Flow | -123.00M | -126.30M | 194.22M | -423.00M | -19.23M | -657.00M |
Octave Specialty Group Technical Analysis
3.94
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSG, the sentiment is undefined. The current price of 3.94 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for OSG.
Octave Specialty Group Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
* Financial Sector Average
Performance Comparison
Octave Specialty Group Corporate Events
Executive/Board ChangesShareholder Meetings
Octave Specialty Group Shareholders Back Governance and Pay Plans
Positive
May 29, 2026
At its annual meeting of stockholders held on May 28, 2026, Octave Specialty Group, Inc. reported that approximately 81% of its outstanding common shares were represented, underscoring strong investor engagement in the company’s governance. ...
Business Operations and StrategyPrivate Placements and Financing
Octave Specialty Group Amends Credit Facility, Adds Term Loan
Positive
Apr 7, 2026
On April 1, 2026, Octave Specialty Group, Inc., acting through several U.S. and U.K. subsidiaries, executed a First Amendment to its existing credit agreement with a syndicate of lenders led by Truist Bank as administrative agent. The amendment ad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.